Summit Therapeutics shares fall as lung cancer trial results disappointProactive Investors • 09/08/25
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping PunchInvestors Business Daily • 09/08/25
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data DifferencesBenzinga • 09/08/25
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 09/08/25
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332PRNewsWire • 09/07/25
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLCBusiness Wire • 09/07/25
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says AnalystBenzinga • 08/27/25
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025Business Wire • 08/14/25
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law FirmPRNewsWire • 08/12/25
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025Business Wire • 08/11/25
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsThe Motley Fool • 07/22/25
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 07/14/25
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks RemainSeeking Alpha • 07/04/25
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeZacks Investment Research • 07/02/25
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant TumorsBusiness Wire • 06/30/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTGlobeNewsWire • 06/23/25